Effects of recombinant human DNase and hypertonic saline on airway inflammation in children with cystic fibrosis

Ranjan Suri, Lindsay J. Marshall, Colin Wallis, Christopher Metcalfe, Andrew Bush, Janis K. Shute

Research output: Contribution to journalArticle

Abstract

Recombinant human DNase (rhDNase) is an established treatment in cystic fibrosis (CF), but it may liberate cationic mediators bound to DNA in the airways. An alternative mucolytic therapy is hypertonic saline (HS); however, HS may potentiate neutrophilic inflammation. We compared the effect of rhDNase and HS on cationic proinflammatory mediators in CF sputum. In a randomized, crossover trial, 48 children with CF were allocated consecutively to 12 weeks of once-daily 2.5 mg rhDNase, alternate-day 2.5 mg rhDNase, and twice-daily 7% HS. Sputum levels of total interleukin-8 (IL-8), free IL-8, myeloperoxidase, eosinophil cationic protein, and neutrophil elastase (NE) activity were measured before and after each treatment. The change in mediator levels from baseline with daily rhDNase and HS was not significant; however, with alternate-day rhDNase, there was an increase in free IL-8. When changes in mediator levels with daily rhDNase were compared with alternate-day rhDNase and HS, no significant differences were detected. Only changes in NE activity were associated with changes in lung function. In summary, we were unable to show that rhDNase or HS promote airway inflammation in CF.
Original languageEnglish
Pages (from-to)352-355
Number of pages4
JournalAmerican Journal of Respiratory and Critical Care Medicine
Volume166
Issue number3
DOIs
Publication statusPublished - 1 Aug 2002

Fingerprint

Cystic Fibrosis
Inflammation
Interleukin-8
Leukocyte Elastase
Sputum
Eosinophil Cationic Protein
Expectorants
dornase alfa
Complementary Therapies
Cross-Over Studies
Peroxidase
Lung
DNA
Therapeutics

Keywords

  • cystic fibrosis
  • saline
  • rhDNase
  • inflammation

Cite this

Suri, Ranjan ; Marshall, Lindsay J. ; Wallis, Colin ; Metcalfe, Christopher ; Bush, Andrew ; Shute, Janis K. / Effects of recombinant human DNase and hypertonic saline on airway inflammation in children with cystic fibrosis. In: American Journal of Respiratory and Critical Care Medicine. 2002 ; Vol. 166, No. 3. pp. 352-355.
@article{6f29d198b8b94115a8458bd9af6c8313,
title = "Effects of recombinant human DNase and hypertonic saline on airway inflammation in children with cystic fibrosis",
abstract = "Recombinant human DNase (rhDNase) is an established treatment in cystic fibrosis (CF), but it may liberate cationic mediators bound to DNA in the airways. An alternative mucolytic therapy is hypertonic saline (HS); however, HS may potentiate neutrophilic inflammation. We compared the effect of rhDNase and HS on cationic proinflammatory mediators in CF sputum. In a randomized, crossover trial, 48 children with CF were allocated consecutively to 12 weeks of once-daily 2.5 mg rhDNase, alternate-day 2.5 mg rhDNase, and twice-daily 7{\%} HS. Sputum levels of total interleukin-8 (IL-8), free IL-8, myeloperoxidase, eosinophil cationic protein, and neutrophil elastase (NE) activity were measured before and after each treatment. The change in mediator levels from baseline with daily rhDNase and HS was not significant; however, with alternate-day rhDNase, there was an increase in free IL-8. When changes in mediator levels with daily rhDNase were compared with alternate-day rhDNase and HS, no significant differences were detected. Only changes in NE activity were associated with changes in lung function. In summary, we were unable to show that rhDNase or HS promote airway inflammation in CF.",
keywords = "cystic fibrosis, saline, rhDNase, inflammation",
author = "Ranjan Suri and Marshall, {Lindsay J.} and Colin Wallis and Christopher Metcalfe and Andrew Bush and Shute, {Janis K.}",
year = "2002",
month = "8",
day = "1",
doi = "10.1164/rccm.2110015",
language = "English",
volume = "166",
pages = "352--355",
journal = "American Journal of Respiratory and Critical Care Medicine",
issn = "1073-449X",
publisher = "American Thoracic Society",
number = "3",

}

Effects of recombinant human DNase and hypertonic saline on airway inflammation in children with cystic fibrosis. / Suri, Ranjan; Marshall, Lindsay J.; Wallis, Colin; Metcalfe, Christopher; Bush, Andrew; Shute, Janis K.

In: American Journal of Respiratory and Critical Care Medicine, Vol. 166, No. 3, 01.08.2002, p. 352-355.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Effects of recombinant human DNase and hypertonic saline on airway inflammation in children with cystic fibrosis

AU - Suri, Ranjan

AU - Marshall, Lindsay J.

AU - Wallis, Colin

AU - Metcalfe, Christopher

AU - Bush, Andrew

AU - Shute, Janis K.

PY - 2002/8/1

Y1 - 2002/8/1

N2 - Recombinant human DNase (rhDNase) is an established treatment in cystic fibrosis (CF), but it may liberate cationic mediators bound to DNA in the airways. An alternative mucolytic therapy is hypertonic saline (HS); however, HS may potentiate neutrophilic inflammation. We compared the effect of rhDNase and HS on cationic proinflammatory mediators in CF sputum. In a randomized, crossover trial, 48 children with CF were allocated consecutively to 12 weeks of once-daily 2.5 mg rhDNase, alternate-day 2.5 mg rhDNase, and twice-daily 7% HS. Sputum levels of total interleukin-8 (IL-8), free IL-8, myeloperoxidase, eosinophil cationic protein, and neutrophil elastase (NE) activity were measured before and after each treatment. The change in mediator levels from baseline with daily rhDNase and HS was not significant; however, with alternate-day rhDNase, there was an increase in free IL-8. When changes in mediator levels with daily rhDNase were compared with alternate-day rhDNase and HS, no significant differences were detected. Only changes in NE activity were associated with changes in lung function. In summary, we were unable to show that rhDNase or HS promote airway inflammation in CF.

AB - Recombinant human DNase (rhDNase) is an established treatment in cystic fibrosis (CF), but it may liberate cationic mediators bound to DNA in the airways. An alternative mucolytic therapy is hypertonic saline (HS); however, HS may potentiate neutrophilic inflammation. We compared the effect of rhDNase and HS on cationic proinflammatory mediators in CF sputum. In a randomized, crossover trial, 48 children with CF were allocated consecutively to 12 weeks of once-daily 2.5 mg rhDNase, alternate-day 2.5 mg rhDNase, and twice-daily 7% HS. Sputum levels of total interleukin-8 (IL-8), free IL-8, myeloperoxidase, eosinophil cationic protein, and neutrophil elastase (NE) activity were measured before and after each treatment. The change in mediator levels from baseline with daily rhDNase and HS was not significant; however, with alternate-day rhDNase, there was an increase in free IL-8. When changes in mediator levels with daily rhDNase were compared with alternate-day rhDNase and HS, no significant differences were detected. Only changes in NE activity were associated with changes in lung function. In summary, we were unable to show that rhDNase or HS promote airway inflammation in CF.

KW - cystic fibrosis

KW - saline

KW - rhDNase

KW - inflammation

UR - https://www.atsjournals.org/doi/full/10.1164/rccm.2110015

U2 - 10.1164/rccm.2110015

DO - 10.1164/rccm.2110015

M3 - Article

C2 - 12153969

VL - 166

SP - 352

EP - 355

JO - American Journal of Respiratory and Critical Care Medicine

JF - American Journal of Respiratory and Critical Care Medicine

SN - 1073-449X

IS - 3

ER -